Cargando…

Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

IMPORTANCE: Hyperprogressive disease (HPD) is a recognized pattern of rapid tumor progression during immune checkpoint inhibitor (ICI) treatment. Definitions of HPD have not been standardized, posing the risk of capturing different tumoral behaviors. OBJECTIVES: To provide a systematic summary of de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Hyo Jung, Kim, Kyung Won, Won, Sang Eun, Yoon, Shinkyo, Chae, Young Kwang, Tirumani, Sree Harsha, Ramaiya, Nikhil H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991969/ https://www.ncbi.nlm.nih.gov/pubmed/33760090 http://dx.doi.org/10.1001/jamanetworkopen.2021.1136

Ejemplares similares

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Efficacy of Immune Checkpoint Inhibitors against Advanced or Metastatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
por: Park, Eun-Joo, et al.
Publicado: (2022)

Cancer genome landscape: a radiologist’s guide to cancer genome medicine with imaging correlates
por: Alessandrino, Francesco, et al.
Publicado: (2019)

Beyond PET/CT in Hodgkin lymphoma: a comprehensive review of the role of imaging at initial presentation, during follow-up and for assessment of treatment-related complications
por: Keraliya, Abhishek R., et al.
Publicado: (2015)

Fluid Retention Associated with Imatinib Treatment in Patients with Gastrointestinal Stromal Tumor: Quantitative Radiologic Assessment and Implications for Management
por: Kim, Kyung Won, et al.
Publicado: (2015)

Molecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to know
por: Tirumani, Sree Harsha, et al.
Publicado: (2013)

Metastatic pattern of uterine leiomyosarcoma: retrospective analysis of the predictors and outcome in 113 patients
por: Tirumani, Sree Harsha, et al.
Publicado: (2014)

Considerations in imaging interpretations for colitis in critically ill patients during the COVID-19 era
por: Martin, Sooyoung, et al.
Publicado: (2021)

Systemic treatment in breast cancer: a primer for radiologists
por: Michaels, Aya Y., et al.
Publicado: (2015)

Imaging Features of Primary Tumors and Metastatic Patterns of the Extraskeletal Ewing Sarcoma Family of Tumors in Adults: A 17-Year Experience at a Single Institution
por: Huh, Jimi, et al.
Publicado: (2015)

An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence
por: Kalisz, Kevin, et al.
Publicado: (2019)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know
por: Braschi-Amirfarzan, Marta, et al.
Publicado: (2017)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors
por: Choi, Yong Jun, et al.
Publicado: (2020)

What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms?
por: Choe, Jooae, et al.
Publicado: (2019)

Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment
por: Kim, Jehun, et al.
Publicado: (2022)

COVID-19 infection in the cancer population: a study of emergency department imaging utilization and findings
por: Vos, Derek, et al.
Publicado: (2021)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

Are asymptomatic gastrointestinal findings on imaging more common in COVID-19 infection? Study to determine frequency of abdominal findings of COVID-19 infection in patients with and without abdominal symptoms and in patients with chest-only CT scans
por: Tirumani, Sree Harsha, et al.
Publicado: (2021)

Extracutaneous melanomas: a primer for the radiologist
por: Keraliya, Abhishek R., et al.
Publicado: (2015)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
por: Wei, Zhanqi, et al.
Publicado: (2022)

Quantifying the decrease in emergency department imaging utilization during the COVID-19 pandemic at a multicenter healthcare system in Ohio
por: Parikh, Keval D., et al.
Publicado: (2020)

COVID-19 Pandemic Impact on Decreased Imaging Utilization: A Single Institutional Experience
por: Parikh, Keval D., et al.
Publicado: (2020)

Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
por: Won, Sang Eun, et al.
Publicado: (2020)

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018)

The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
por: Sabio, Erich, et al.
Publicado: (2019)

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor
por: Xu, Zihan, et al.
Publicado: (2019)

Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
por: Schuiveling, M., et al.
Publicado: (2020)

Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review
por: Liu, Xiaojun, et al.
Publicado: (2022)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Malignant abdominal rocks: where do they come from?
por: Cheng, Joan M., et al.
Publicado: (2013)

Impact of COVID-19 Vaccine Administration on Radiology Department Workflow: A Single Academic Center Experience
por: Chagarlamudi, Kaushik, et al.
Publicado: (2021)

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
por: Camelliti, Simone, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u4rl8tutronb4l5kpv3982tc3n